Dacomitinib

Chemical formula: C₂₄H₂₅ClFN₅O₂  Molecular mass: 469.939 g/mol  PubChem compound: 11511120

Therapeutic indications

Dacomitinib is indicated for:

Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations

Population group: only adults (18 years old or older)

Dacomitinib, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: VIZIMPRO Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈